Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial
Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial. // The Breast. – URL: https://www.sciencedirect.com/science/article/pii/S0960977626002146?dgcid=rss_sd_all
Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial. The Breast. https://www.sciencedirect.com/science/article/pii/S0960977626002146?dgcid=rss_sd_all
“Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial.” The Breast.
@article{article67589,
title = {Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial},
journal = {The Breast},
url = {https://www.sciencedirect.com/science/article/pii/S0960977626002146?dgcid=rss_sd_all}
}
ABSTRACT Objectives The aim of this study was to determine whether certain cephalometric findings can predict the future need for orthognathic surgery (OS) in cleft lip (CL), cleft palate (CP), unilateral cleft lip and palate (UCLP),...